{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:47:57Z","timestamp":1788616077295,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy of venetoclax\u2010azacitidine (VEN\u2013AZA) with AZA in the real\u2010life for patients with first relapsed or refractory acute myeloid leukaemia (R\/R AML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed R\/R AML patients treated with VEN\u2013AZA at the Institut Paoli Calmettes between September 2020 and February 2022. We compared them to a historical cohort of patients treated with AZA between 2010 and 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010five patients treated with VEN\u2013AZA were compared with 140 patients treated with AZA. There were more favourable cytogenetics (25.7% vs. 8.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) and less FLT3\u2010ITD mutated AML (8.8% vs. 25.5%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.049) in the VEN\u2013AZA group. The overall 30\u2010day mortality rate was 7.4% and the overall 90\u2010day mortality was 20%, with no difference between the groups. The complete remission rate was 48.6% in the VEN\u2013AZA group versus 15% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001). The composite complete response rate was 65.7% in the VEN\u2013AZA group versus 23.6% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.0001). OS was 12.8\u2009months in the VEN\u2013AZA group versus 7.3\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.059). Patients with primary refractory AML, poor\u2010risk cytogenetics, prior hematopoietic stem\u2010cell transplantation (HSCT) and FLT3\u2010ITD mutated AML had lower response and survival rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VEN\u2013AZA was associated with a better response rate and a longer survival than AZA monotherapy in AML patients who relapsed after or were refractory to\u00a0intensive chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.14140","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T01:19:23Z","timestamp":1701307163000},"page":"530-537","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Azacitidine\u2013venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients"],"prefix":"10.1111","volume":"112","author":[{"given":"C.","family":"Petit","sequence":"first","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saillard","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mohty","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hicheri","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Villetard","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Maisano","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Charbonnier","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rey","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"D\u2018Incan","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rouzaud","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gelsi\u2010Boyer","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie des Tumeurs CRCM Inserm, CNRS, Institut Paoli\u2010Calmettes, Aix\u2010Marseille Univ  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Murati","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie des Tumeurs Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Lhoumeau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie des Tumeurs Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ittel","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie des Tumeurs Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Mozziconacci","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie des Tumeurs Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Alary","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie des Tumeurs Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010A.","family":"Hospital","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie Institut Paoli\u2010Calmettes  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vey","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie, CRCM Inserm, CNRS, Institut Paoli\u2010Calmettes, Aix\u2010Marseille Univ  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Garciaz","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'h\u00e9matologie, CRCM Inserm, CNRS, Institut Paoli\u2010Calmettes, Aix\u2010Marseille Univ  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25975"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016121"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.11.009"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.003"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2022140"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188094"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2042688"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082025"},{"issue":"4","key":"e_1_2_10_14_1","article-title":"Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies","volume":"5","author":"Feld J","year":"2021","journal-title":"Hema"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169509"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003734"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03719-6"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25567"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1761964"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03911-z"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221081637"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33814"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26601"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16268"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014241"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00602"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153571"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0205"},{"key":"e_1_2_10_31_1","unstructured":"Clinicaltrials.gov.IMGN632 as monotherapy or with venetoclax and\/or azacitidine for patients with CD123\u2010positive acute myeloid leukemia [Internet].2019Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04086264?term=IMGN&cond=Myeloid+Malignancy&draw=2&rank=3"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T01:14:27Z","timestamp":1714612467000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/ejh.14140"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14140","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"2023-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}